Tom Fitzgerald, who is the CFO of a publicly traded company, is involved in developments concerning the FDA and market valuation.
3 reports, 1 independent
Updated Sep 16
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tom Fitzgerald, who is the CFO of a publicly traded company, is involved in developments concerning the FDA and market valuation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tom Fitzgerald
American journalist
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Cantor Fitzgerald provided research reports on Cabaletta Bio, a company whose stock trades on Nasdaq.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.